AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29415606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen medicated plaster
Number of subjects: 210
Study 29415606 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 210
Study 26611500 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% SSS in ET medium (Group A)
Number of subjects: 750
Study 26611500 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% SSS in ET medium (Group B)
Number of subjects: 750
Study 26611500 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% SSS in ET medium (Group C)
Number of subjects: 750
Study 24849439 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Narcotrend index maintained at D0 level)
Number of subjects: 105
Study 24849439 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (Narcotrend index maintained at D2 level)
Number of subjects: 105
Study 24849439 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (Narcotrend index maintained at E1 level)
Number of subjects: 105
Study 22929601 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% sucrose
Number of subjects: 113
Study 22929601 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% sucrose
Number of subjects: 113
Study 22929601 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 113
Study 20558197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 2203
Study 17378911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin concentration greater than 3,200 pg/mL (fourth quartile)
Number of subjects: 52
Study 17378911 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight subjects (BMI >= 25)
Number of subjects: 52
Study 15741228 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fluoroscopic navigation system
Number of subjects: 72
Study 15741228 — intervention group
Group type: COMPARATOR
Intervention: Control group (without non-fluoroscopic navigation)
Number of subjects: 72
Study 11931786 — intervention group
Group type: COMPARATOR
Intervention: 1 Gy (4 x 0.25 Gy)
Number of subjects: 161
Study 11931786 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy (4 x 2 Gy)
Number of subjects: 161
Study 11931786 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy (4 x 4 Gy)
Number of subjects: 161
Study 9788404 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (5-fluorouracil, mitomycin C, and radiation therapy)
Number of subjects: 0
Study 9788404 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 8607315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 0.1 mg/kg
Number of subjects: 12
Study 8607315 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 2650015 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir in propylenglycol (40% cream)
Number of subjects: 96
Study 2650015 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 96
Study 769975 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC, BCNU, and vincristine
Number of subjects: 0
Study 769975 — intervention group
Group type: COMPARATOR
Intervention: DTIC, BCNU, and actinomycin D
Number of subjects: 0
Study 769975 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin and DTIC
Number of subjects: 0
Study 769975 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine, and methotrexate
Number of subjects: 0
Study 769975 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (adriamycin, bleomycin, vinblastine, and DTIC)
Number of subjects: 0
Study 769975 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, prednisone, and procarbazine)
Number of subjects: 0
Study 31617562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical geriatric assessments and collaborative medication reviews by geriatrician and family physician (FP)
Number of subjects: 174
Study 31617562 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 174
Study 31185323 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT + nystatin
Number of subjects: 66
Study 31185323 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 66
Study 28118537 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 811 (180 mg)
Number of subjects: 16
Study 28118537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25811379 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor Residual Spraying (IRS) in addition to Insecticide Treated Nets (ITNs)
Number of subjects: 50
Study 25811379 — intervention group
Group type: COMPARATOR
Intervention: Insecticide Treated Nets (ITNs)
Number of subjects: 50
Study 25811379 — intervention group
Group type: COMPARATOR
Intervention: Living in a sprayed village
Number of subjects: 50
Study 23652892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene foam, 0.1%
Number of subjects: 1486
Study 23652892 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 1486
Study 21814547 — intervention group
Group type: EXPERIMENTAL
Intervention: TCF7L2 rs7903146 T allele
Number of subjects: 2994
Study 19264723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 186
Study 19264723 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone-iodine
Number of subjects: 186
Study 17455207 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend 5-ASA enema (1 g twice a week) plus oral 5-ASA (3 g/day)
Number of subjects: 24
Study 17455207 — intervention group
Group type: COMPARATOR
Intervention: Oral 5-ASA only (3 g/day)
Number of subjects: 24
Study 14522627 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 4% gel (BID)
Number of subjects: 178
Study 14522627 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% gel (QD)
Number of subjects: 178
Study 10968648 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in combination with tooth extraction
Number of subjects: 22
Study 10968648 — intervention group
Group type: COMPARATOR
Intervention: Routine tooth extraction alone (control group)
Number of subjects: 22
Study 10968648 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture used in combination with local anesthesia
Number of subjects: 22
Study 9202556 — intervention group
Group type: EXPERIMENTAL
Intervention: SR alfuzosin 5 mg twice daily
Number of subjects: 588
Study 9202556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 1283576 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR 240 mg/day
Number of subjects: 1464
Study 1283576 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 1464
Study 1283576 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1464
Study 3823637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg sublingually)
Number of subjects: 8
Study 3823637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31072706 — intervention group
Group type: EXPERIMENTAL
Intervention: MV ≥24 hours
Number of subjects: 1994
Study 31072706 — intervention group
Group type: EXPERIMENTAL
Intervention: MV ≥36 hours
Number of subjects: 1994
Study 31072706 — intervention group
Group type: EXPERIMENTAL
Intervention: MV ≥48 hours
Number of subjects: 1994
Study 31072706 — intervention group
Group type: EXPERIMENTAL
Intervention: Model performance for predicting prolonged MV
Number of subjects: 1994
Study 28415881 — intervention group
Group type: EXPERIMENTAL
Intervention: Step by Step treatment protocol (intervention)
Number of subjects: 57
Study 27367159 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 20 mg once daily (up to 40 mg once daily for 4 weeks if required)
Number of subjects: 30
Study 25069531 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg metoclopramide thrice daily for 15 days
Number of subjects: 36
Study 25069531 — intervention group
Group type: COMPARATOR
Intervention: 10‐mg placebo thrice daily for 15 days
Number of subjects: 36
Study 22614994 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-exercise intervention delivered via mailed print materials and telephone counseling
Number of subjects: 641
Study 22614994 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 641
Study 19272808 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Number of subjects: 120
Study 19272808 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (splint, heat, and exercise)
Number of subjects: 120
Study 17289855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral eccentric overload strength training using the Bromsman device twice a week
Number of subjects: 20
Study 17289855 — intervention group
Group type: COMPARATOR
Intervention: Unilateral eccentric body load training using a decline board twice a week
Number of subjects: 20
Study 15336780 — intervention group
Group type: EXPERIMENTAL
Intervention: MART-1(27-35) peptide-pulsed autologous APC
Number of subjects: 0
Study 15336780 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-1(161-169) peptide-pulsed APC
Number of subjects: 0
Study 15336780 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate-pulsed APC
Number of subjects: 0
Study 15336780 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-vaccine PBL
Number of subjects: 0
Study 11148437 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole-based triple therapy for 7 days
Number of subjects: 161
Study 11148437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 9565943 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged intermittent high intensity shuttle run (PHISR)
Number of subjects: 8
Study 9565943 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuttle-run (SR)
Number of subjects: 8
Study 9565943 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill run (TR)
Number of subjects: 8
Study 9565943 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no exercise)
Number of subjects: 8
Study 8929937 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness for treatment
Number of subjects: 494
Study 8929937 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment tenure
Number of subjects: 494
Study 2780404 — intervention group
Group type: EXPERIMENTAL
Intervention: Winningham Aerobic Interval Training (WAIT) exercise program, 60%-85% of maximal heart rate for 20-30 minutes, 3 times per week, for 10-12 weeks
Number of subjects: 24
Study 2780404 — intervention group
Group type: COMPARATOR
Intervention: No exercise treatment (Control Group)
Number of subjects: 24
Study 329423 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (0.022 mg/kg and 0.044 mg/kg)
Number of subjects: 10
Study 329423 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol
Number of subjects: 10
Study 329423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 329423 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (Valium)
Number of subjects: 10
Study 31818699 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual film (10-35 mg)
Number of subjects: 109
Study 31818699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 31818699 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual film
Number of subjects: 109
Study 31761524 — intervention group
Group type: EXPERIMENTAL
Intervention: NSA‐12 (Negative Symptom Assessment-12)
Number of subjects: 274
Study 31761524 — intervention group
Group type: EXPERIMENTAL
Intervention: NSA‐16 (Negative Symptom Assessment-16)
Number of subjects: 274
Study 27858282 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Program (n=240)
Number of subjects: 479
Study 27858282 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition (n=239)
Number of subjects: 479
Study 26472122 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose X-ray system with advanced real-time image processing
Number of subjects: 50
Study 26472122 — intervention group
Group type: COMPARATOR
Intervention: Reference X-ray system
Number of subjects: 50
Study 23196311 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30
Study 23196311 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study 23196311 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 30
Study 21311578 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaGel
Number of subjects: 54
Study 21311578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19811649 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp/SP
Number of subjects: 648
Study 19811649 — intervention group
Group type: COMPARATOR
Intervention: CWC/CQ
Number of subjects: 648
Study 19811649 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp/CQ
Number of subjects: 648
Study 16507327 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprinocarsen (2mg/kg/day continuous iv infusion for the first 14 days of each cycle), combined with gemcitabine (1,250 mg/m² on days 1 and 8) and carboplatin (AUC 5 on day 1 every 21 days).
Number of subjects: 36
Study 16507327 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin (without aprinocarsen).
Number of subjects: 36
Study 14747106 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoComb (TC)
Number of subjects: 189
Study 14747106 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (suturing)
Number of subjects: 189
Study 11757472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg)
Number of subjects: 24
Study 11757472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11757472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 24
Study 9164203 — intervention group
Group type: EXPERIMENTAL
Intervention: Six cycles of standard adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy
Number of subjects: 488
Study 9164203 — intervention group
Group type: COMPARATOR
Intervention: One cycle of perioperative CMF therapy
Number of subjects: 488
Study 8394880 — intervention group
Group type: EXPERIMENTAL
Intervention: ImuVert and radiation therapy (RT)
Number of subjects: 15
Study 6691885 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (information about side-effects) and Group B (information about beneficial effects) combined
Number of subjects: 120
Study 6691885 — intervention group
Group type: COMPARATOR
Intervention: Group B (information about beneficial effects)
Number of subjects: 120
Study 6691885 — intervention group
Group type: COMPARATOR
Intervention: Group C (no information)
Number of subjects: 120
Study 6691885 — intervention group
Group type: COMPARATOR
Intervention: Group A (information about side-effects)
Number of subjects: 120
Study 30513463 — intervention group
Group type: EXPERIMENTAL
Intervention: CASEL School Guide implementation model
Number of subjects: 14
Study 29864779 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar (10 mg initial dose, potentially an additional 10 mg based on aggregometry)
Number of subjects: 16
Study 29864779 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 16
Study 27583648 — intervention group
Group type: EXPERIMENTAL
Intervention: Golf-Specific Resistance Training (GSRT)
Number of subjects: 45
Study 27583648 — intervention group
Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRAD)
Number of subjects: 45
Study 27583648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TRAD and GSRT
Number of subjects: 45
Study 24125514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Number of subjects: 70
Study 24125514 — intervention group
Group type: COMPARATOR
Intervention: Conventional polypectomy
Number of subjects: 70
Study 22049096 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily for six months
Number of subjects: 31
Study 22049096 — intervention group
Group type: COMPARATOR
Intervention: Metformin 850 mg twice daily for six months
Number of subjects: 31
Study 19575048 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Toothbrush (PT)
Number of subjects: 109
Study 19575048 — intervention group
Group type: COMPARATOR
Intervention: Manual Toothbrush (MT)
Number of subjects: 109
Study 17172551 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight support treadmill training (BWSTT)
Number of subjects: 145
Study 17172551 — intervention group
Group type: COMPARATOR
Intervention: Conventional overground mobility intervention (CONT)
Number of subjects: 145
Study 17172551 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (BWSTT and CONT)
Number of subjects: 145
Study 16551284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis dose defined by K/DOQI guidelines (spKt/V of 1.2)
Number of subjects: 0
Study 16551284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis dose defined by European guidelines (spKt/V of 1.4)
Number of subjects: 0
Study 16551284 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of dialysis dose for low molecular weight water-soluble solutes (urea)
Number of subjects: 0
Study 16551284 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of spKt/V or eKt/V for routine monitoring of hemodialysis dose
Number of subjects: 0
Study 16551284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis dose dependent on gender
Number of subjects: 0
Study 16551284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis dose for middle molecules in clinical practice
Number of subjects: 0
Study 16551284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis dose for more frequent hemodialysis treatment strategies
Number of subjects: 0
Study 15451901 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine/NPH (n = 435)
Number of subjects: 876
Study 15451901 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (RHI)/NPH (n = 441)
Number of subjects: 876
Study 10633218 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose infusion of insulin (HDT)
Number of subjects: 10
Study 10633218 — intervention group
Group type: COMPARATOR
Intervention: Low dose infusion of insulin (LDT)
Number of subjects: 10
Study 8659772 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release ibuprofen, 2 x 800 mg (n = 57)
Number of subjects: 115
Study 8659772 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 58)
Number of subjects: 115
Study 2058222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (400 mg)
Number of subjects: 8
Study 2058222 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline administered via endoscope into the colon transversum
Number of subjects: 8
Study 6097457 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-9 analogue (40 mg)
Number of subjects: 6
Study 6097457 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 6
Study 6097457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31246579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (2000-2500 g)
Number of subjects: 2000
Study 31246579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (2500-3000 g)
Number of subjects: 2000
Study 31246579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (3000-3500 g)
Number of subjects: 2000
Study 31246579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (3500-4000 g)
Number of subjects: 2000
Study 31246579 — intervention group
Group type: COMPARATOR
Intervention: Males vs Females
Number of subjects: 2000
Study 31246579 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2000
Study 28810909 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil-guided corticosteroid-sparing therapy (prednisolone not administered if eosinophil level < 0.3 × 10^9 cells/L)
Number of subjects: 320
Study 28810909 — intervention group
Group type: COMPARATOR
Intervention: Standard care (5-day course of high-dose systemic corticosteroids)
Number of subjects: 320
Study 28810909 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil-guided corticosteroid-sparing therapy
Number of subjects: 320
Study 25504427 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible breast compression paddle (FP)
Number of subjects: 288
Study 25504427 — intervention group
Group type: COMPARATOR
Intervention: Rigid breast compression paddle (RP)
Number of subjects: 288
Study 22821925 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided pararadicular injections
Number of subjects: 40
Study 22821925 — intervention group
Group type: COMPARATOR
Intervention: CT-controlled interventions
Number of subjects: 40
Study 21082298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral caffeine 200 mg
Number of subjects: 90
Study 21082298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral caffeine 400 mg
Number of subjects: 90
Study 21082298 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 90
Study 19118324 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 or 30 mg/day)
Number of subjects: 485
Study 19118324 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (5-15 mg/day)
Number of subjects: 485
Study 19118324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 19118324 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 485
Study 16511899 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (Adjuvant!)
Number of subjects: 405
Study 15195725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pin-retained amalgam restorations (self-threading stainless steel pins)
Number of subjects: 60
Study 15195725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations (filled, 4-META-based bonding resin)
Number of subjects: 60
Study 15195725 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 60
Study 11242608 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled flunisolide, 500 mg twice a day for 2 years
Number of subjects: 29
Study 11242608 — intervention group
Group type: COMPARATOR
Intervention: Control group (asthma patients not requiring glucocorticoid treatment)
Number of subjects: 29
Study 9060365 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoscope
Number of subjects: 0
Study 9060365 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 0